Showing results (191-200 of 229) with videos related to

Sort By:
Pageof 23
European Journal of Medicinal Chemistry|June 7, 2026
Design, synthesis, and evaluation of novel thieno[2,3-b]pyridine derivatives as DRAK2 inhibitorsYuhang Shu, Bingqian Zhang, Yuxin Zhang, et al.
Frontiers in Endocrinology|March 21, 2018
Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation CarrierDandan Zhao, Shaoqian Zhao, Xiao Wang, et al.
QJM : Monthly Journal of the Association of Physicians|February 5, 2026
Effect of Yiqi Fumai injection improves exercise tolerance in patients with chronic heart failure: A prospective, open-label, randomized, controlled clinical trialYunfeng Jia, Lu Fan, Lei Wei, et al.
Science Advances|February 7, 2024
AMPK phosphorylation of FNIP1 (S220) controls mitochondrial function and muscle fuel utilization during exerciseLiwei Xiao, Yujing Yin, Zongchao Sun, et al.
European Journal of Medicinal Chemistry|October 18, 2025
Novel thieno[2,3-b]pyridine derivatives protect islet through DRAK2 kinase inhibitionKaiyue Lian, Ruihan Li, Yuting Lu, et al.
Journal of Medicinal Chemistry|May 13, 2024
Discovery of Oral AMP-Activated Protein Kinase Activators for Treating HyperlipidemiaMingchao Wang, Zunsheng Han, Baoyan Fan, et al.
Plos One|September 7, 2012
BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinaseWanhua Lin, Xiaoli Huang, Lina Zhang, et al.
European Journal of Medicinal Chemistry|August 29, 2014
Design, synthesis and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitorsXun Ji, Chunmei Xia, Jiang Wang, et al.
Bioorganic & Medicinal Chemistry|March 3, 2006
Design, synthesis, and evaluation of Leu*Ala hydroxyethylene-based non-peptide beta-secretase (BACE) inhibitorsKun Xiao, Xin Li, Jingya Li, et al.
Cell Death & Disease|September 18, 2020
The triterpenoid sapogenin (2α-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodellingZhifu Xie, Haowen Jiang, Wei Liu, et al.
Pageof 23